OTC:NWBO

NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO

BETHESDA, Maryland, June 1, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that onSunday, June 3, at 4:15 p.m. Central Time in the Industry Expert Theater in the Exhi...

2018-06-01 00:40 2062